1. An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.

    Journal of Proteome Research 14(2):654 (2015) PMID 25490617

    Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow...
  2. An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.

    Journal of Proteome Research 14(2):654 (2015) PMID 25490617

    Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow...
  3. Predicting progression from cognitive impairment to Alzheimer's disease with the disease state index.

    Current Alzheimer Research 12(1):69 (2015) PMID 25523428

    We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer's disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients' similarity to di...
  4. Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function.

    Journal of Alzheimer's Disease 44(4):1313 (2015) PMID 25420549

    Glycogen synthase kinase 3 beta (GSK3B) is the major kinase phosphorylating tau protein. Hyperphosphorylated tau is one of the hallmarks of Alzheimer's disease (AD). Despite extensive research, the role of GSK3B in AD pathogenesis is not fully understood. To evaluate possible associations betwee...
  5. Predicting progression from cognitive impairment to Alzheimer's disease with the disease state index.

    Current Alzheimer Research 12(1):69 (2015) PMID 25523428

    We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer's disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients' similarity to di...
  6. Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function.

    Journal of Alzheimer's Disease 44(4):1313 (2015) PMID 25420549

    Glycogen synthase kinase 3 beta (GSK3B) is the major kinase phosphorylating tau protein. Hyperphosphorylated tau is one of the hallmarks of Alzheimer's disease (AD). Despite extensive research, the role of GSK3B in AD pathogenesis is not fully understood. To evaluate possible associations betwee...
  7. Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients.

    BMC Geriatrics 15(1):65 (2015) PMID 26076825 PMCID PMC4469410

    The diagnostic workup in dementia includes brain imaging with reading focussed on signs of cerebrovascular and neurodegenerative disease. We hypothesised that these findings may be underreported in hospital patients, where imaging is often performed to rule out obvious pathology such as haemorrh...
  8. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.

    Alzheimer's Research & Therapy 7(1):40 (2015) PMID 26136856 PMCID PMC4487851

    Synaptic dysfunction and degeneration are central events in Alzheimer's disease (AD) pathophysiology that are thought to occur early in disease progression. Synaptic pathology may be studied by examining protein biomarkers specific for different synaptic elements. We recently showed that the den...
  9. Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index.

    Current Alzheimer Research 12(1):69 (2015) PMID 25523428

    We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer's disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients' similarity to di...
  10. Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness.

    Cerebrovascular Diseases Extra 5(2):41 (2015) PMID 26120319 PMCID PMC4478329

    Arterial stiffness reflects the ageing processes in the vascular system, and studies have shown an association between reduced cognitive function and cerebral small vessel disease. Small vessel disease can be visualized as white matter hyperintensities (WMH) and lacunar infarcts but also as cere...
  11. The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?

    Alzheimer's & Dementia 10(6):713 (2014) PMID 24721526

    We aimed to identify the most useful definition of the "cerebrospinal fluid Alzheimer profile," based on amyloid-ß1-42 (Aβ42), total tau, and phosphorylated tau (p-tau), for diagnosis and prognosis of Alzheimer's disease (AD). We constructed eight Alzheimer profiles with previously published com...
  12. Nonlinear association between pulse wave velocity and cognitive function: a population-based study.

    Journal of Hypertension 32(11):2152 (2014) PMID 25275244

    Arterial stiffness has been hypothesized to contribute to cognitive decline. However, previous studies have reported inconsistent results. The aim of this cross-sectional study was to investigate the association between carotid-femoral pulse wave velocity (cfPWV), a marker of arterial stiffness,...
  13. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

    Alzheimer's & Dementia 10(6):713 (2014) PMID 24721526

    We aimed to identify the most useful definition of the "cerebrospinal fluid Alzheimer profile," based on amyloid-ß1-42 (Aβ42), total tau, and phosphorylated tau (p-tau), for diagnosis and prognosis of Alzheimer's disease (AD). We constructed eight Alzheimer profiles with previously published com...
  14. Nonlinear association between pulse wave velocity and cognitive function: a population-based study.

    Journal of Hypertension 32(11):2152 (2014) PMID 25275244

    Arterial stiffness has been hypothesized to contribute to cognitive decline. However, previous studies have reported inconsistent results. The aim of this cross-sectional study was to investigate the association between carotid-femoral pulse wave velocity (cfPWV), a marker of arterial stiffness,...
  15. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

    Alzheimer's & Dementia 10(6):713 (2014) PMID 24721526

    We aimed to identify the most useful definition of the "cerebrospinal fluid Alzheimer profile," based on amyloid-ß1-42 (Aβ42), total tau, and phosphorylated tau (p-tau), for diagnosis and prognosis of Alzheimer's disease (AD). We constructed eight Alzheimer profiles with previously published com...
  16. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

    JAMA Neurology 71(10):1282 (2014) PMID 25155658

    Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine clinical practice can reliably predict cortical β-amyloid (Aβ) deposition. To study whether CSF biomarkers, analyzed consecutivel...
  17. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

    JAMA Neurology 71(10):1282 (2014) PMID 25155658

    Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine clinical practice can reliably predict cortical β-amyloid (Aβ) deposition. To study whether CSF biomarkers, analyzed consecutivel...
  18. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

    JAMA Neurology 71(10):1282 (2014) PMID 25155658

    Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine clinical practice can reliably predict cortical β-amyloid (Aβ) deposition. To study whether CSF biomarkers, analyzed consecutivel...
  19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

    JAMA Psychiatry 71(10):1183 (2014) PMID 25162367

    Several studies suggest that the apolipoprotein E (APOE) ε4 allele modulates cerebrospinal fluid (CSF) levels of β-amyloid 42 (Aβ42). Whether this effect is secondary to the association of the APOE ε4 allele with cortical Aβ deposition or whether APOE ε4 directly influences CSF levels of Aβ42 in...
  20. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

    JAMA Psychiatry 71(10):1183 (2014) PMID 25162367

    Several studies suggest that the apolipoprotein E (APOE) ε4 allele modulates cerebrospinal fluid (CSF) levels of β-amyloid 42 (Aβ42). Whether this effect is secondary to the association of the APOE ε4 allele with cortical Aβ deposition or whether APOE ε4 directly influences CSF levels of Aβ42 in...